期刊文献+

左西孟旦、硝普钠和多巴酚丁胺治疗急性心力衰竭的临床疗效对比 被引量:3

Comparison of Clinical Efficacy of Levosimendan, Sodium Nitroprusside and Dobutamine in the Treatment of Acute Heart Failure
在线阅读 下载PDF
导出
摘要 目的 :研究左西孟旦、硝普钠与多巴酚丁胺治疗急性心力衰竭的临床疗效。方法 :选取我院收治的急性心力衰竭患者120例,按随机数字表法分为A组、B组和C组,各40例。A组予以左西孟旦[0.5μg/(kg·min)]治疗,B组予以硝普钠[0.5μg/(kg·min)]治疗,C组予以多巴酚丁胺[2.5μg/(kg·min)]治疗,三组均连续治疗14 d。比较三组临床疗效,治疗前后血清因子及心功能。结果 :治疗后,A组血清因子肌钙蛋白(hs-c Tn T)、超敏C反应蛋白(hs-CRP)、B型脑钠肽(BNP)低于B组和C组,差异有统计学意义(P <0.05);治疗后A组左心室收缩末期内径(LVESd)、左心室射血分数(LVEF)优于B组和C组,差异有统计学意义(P <0.05);A组治疗总有效率高于B组和C组,差异有统计学意义(P <0.05)。结论 :与硝普钠、多巴酚丁胺比较,左西孟旦治疗急性心力衰竭的疗效更显著,可调节血清因子水平,促进心功能恢复。 Objective:To study the clinical efficacy of levosimendan,sodium nitroprusside and dobutamine in the treatment of acute heart failure.Methods:120 patients with acute heart failure admitted to our hospital were randomly divided into group A(n=40),group B(n=40)and group C(n=40).The patients in the group A were treated with levosimendan(0.5μg/(kg·min))The patients in the group B was treated with sodium nitroprusside(0.5μg/(kg·min))The patients in the group C was treated with dobutamine(2.5μg/(kg·min))All patients in the three groups were treated for 14 days.The clinical efficacy,serum factors and cardiac functions before and after treatment were compared between the three groups.Results:After treatment,the levels of serum factor troponin(hs-cTnT),high-sensitivity C-reactive protein(hs-CRP)and B-type brain natriuretic peptide(BNP)in the groups A were lower than those in the group B and the group C,and the differences were statistically significant(P<0.05).After treatment,the left ventricular end systolic diameter(LVESd)and left ventricular ejection fraction(LVEF)in the group A were better than those in the group B and the group C,and the differences were statistically significant(P<0.05).The total effective rate in the group A was higher than that in the group B and the group C,and the differences were statistically significant(P<0.05).Conclusion:Compared with sodium nitroprusside and dobutamine,levosimendan is more effective in the treatment of acute heart failure,which can regulate serum factor levels and promote cardiac function recovery.
作者 刘芳芳 Liu Fang-fang(Department of Internal Medicine,People’s Hospital of Zhongzhan District,Jiaozuo Henan 454191,China)
出处 《中国合理用药探索》 CAS 2019年第8期19122-19124,19127,共4页 Chinese Journal of Rational Drug Use
关键词 左西孟旦 硝普钠 多巴酚丁胺 急性心力衰竭 Levosimendan Sodium Nitroprusside Dobutamine Acute Heart Failure
作者简介 刘芳芳,女,主治医师。研究方向:心内科。E-mail:aopanhao538952@163.com
  • 相关文献

二级参考文献49

  • 1杨杰孚,王华.2015年《HFA/ESC/EuSEM/SAEM急性心力衰竭入院前及院内早期管理的建议》解读[J].中国循环杂志,2015,30(S02):6-7. 被引量:6
  • 2Roger V L. Epidemiology of heart failure [J]. Circ Res, 2013, 113(6): 646-659.
  • 3Nieminen M S, Fruhwald S, Heunks L, et al. Levosimendan: current data, clinical use and future development [J]. Heart Lung Vessels, 2013, 5(4): 227-245.
  • 4Bonios M J, Terrovitis J V, Drakos S G~ et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure [J]. lnt J Cardiol, 2012, 159(3): 225-229.
  • 5Malfatto G, Della Rosa F, Villani A, et al. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular fimction, neurohormonal balance, and one-year survival [J]. J Cardiovasc Pharmacol, 2012, 60(5): 450-455.
  • 6Altenberger J, Parissis J T, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial [J]. Eur J Heart Fail, 2014, 16(8): 898-906.
  • 7Rauch H, Motsch J, B6ttiger B W. Newer approaches to the pharmacological management of heart failure [J]. Curr Opin Anaesthesiol, 2006, 19(1): 75-81.
  • 8Yeo P S. Levosimendan in end-stage heart failure [J]. JACC Heart Fail, 2013, 1(4): 365.
  • 9Nieminen M S, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus [J]. Int J Cardiol, 2014, 174(2): 360-367.
  • 10Silvetti S, Greco T, Di Prima A L, et al. Intermittent levosimendan improves mid-term survival in chronicheart failure patients: meta-analysis of randomised trials [J]. Clin Res Cardiol, 103 (7) (2014) 505-513.

共引文献124

同被引文献37

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部